P180 Immune-Oncology (IO) – Tyrosine Kinase Inhibitor (TKI) or IO-IO as first-line treatment in metastatic renal cell carcinoma: What is better in real-world practice? by Stativko, O., Pokataev, I., Tsareva, E., Fedorova, A., Zueva, E., Ibragimova, M., Cherniaev, V., Oskarev, A., Sinitsyna, O., Gridneva, Y., Antonova, T., Volkova, M., Fedyanin, M., Galkin, V.

Get full text